+13.1%
GSK vs BBIO
+26.8%
-13.7%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | BBIO | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.0% | +5.2% | -0.2% | +4.6% |
| 7D | +4.9% | +10.0% | -5.0% | +4.1% |
| 30D | +9.9% | +17.8% | -7.9% | +8.4% |
| 3M | +0.2% | -5.1% | +5.3% | +0.2% |
| 6M | +2.3% | +12.9% | -10.6% | +1.3% |
| YTD | +7.1% | +1.8% | +5.2% | +5.4% |
| 1Y | +13.1% | +26.9% | -13.8% | +4.6% |
| All | +13.1% | +26.8% | -13.7% | +4.6% |
Cumulative growth
Daily Returns
Daily percentage return beside BBIO.
Daily Out/Under-Performance
Portfolio return minus BBIO return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × BBIO return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded BBIO wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling